Cycloserine - Tikvah Therapeutics
Alternative Names: D-cycloserine - Tikvah; TIK-101Latest Information Update: 02 Oct 2021
At a glance
- Originator Therapade Technologies LLC
- Developer Tikvah Therapeutics
- Class Antituberculars; Isoxazoles; Small molecules
- Mechanism of Action NMDA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obsessive-compulsive disorders; Panic disorder; Phobic disorders; Post-traumatic stress disorders; Social phobia
Most Recent Events
- 02 Aug 2007 Phase-II clinical trials in Obsessive-compulsive disorders in USA (unspecified route)
- 02 Aug 2007 Phase-II trials in Phobic disorders in USA (unspecified route)
- 02 Aug 2007 Phase-II trials in Post-traumatic stress disorder in USA (unspecified route)